,i #aagth ,,congress #b;d ,session ,h4 ,r4 #figc ,,in ,,the ,,house ,,of ,,representatives ,march #h1 #bjbb ,mr4 ,carter of ,georgia introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to clarify the conditions under which the ,secretary of ,health and ,human ,services can approve generic drug applications with labeling temporarily different than the brand name drug1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,enhanced ,access to ,affordable ,medicines ,act of #bjbb4 #b4 ,clarifying the conditions of generic drug application approval for last-minute brand name drug labeling changes ,section #eje7;j77#aj77;,a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;j77#aj77;,a77 is amended by striking clauses 7i7 through 7iv7 and inserting the following3 7i7 the application is otherwise eligible for approval under this subsection except that-- 7,i7 7aa7 the listed drug has an active patent1 the listed drug has an active exclusivity period1 or there is a delay in approval as described in paragraph 7#e77;,b77iii72 and 7bb7 a revision to the labeling of the listed drug has been approved by the ,secretary within #ij days of expiration of a patent1 exclusivity period1 or delay in approval referenced in item 7aa72 or 7,,ii7 a revision to the labeling of the listed drug has been approved by the ,secretary1 within #ij days of when the application is otherwise eligible for approval under this subsection2 7ii7 the sponsor of the application agrees to submit revised labeling for the drug that is the subject of the application not later than #fj days after approval under this subsection of the application2 and 7iii7 the labeling revision described under clause 7i7 does not include a change to the ,warnings section of the labeling4 4